McKesson Specialty certified to launch Revlimid
McKesson Specialty, a subsidiary of McKesson Corp., has been certified by Celgene Corp. as one of a select group of RevAssist Program contract pharmacies to launch Revlimid (lenalidomide). To reduce fetal exposure to the drug, Revlimid is available only through RevAssist, a distribution network employing only certified, contracted specialty pharmacies.
McKesson Specialty certified to launch Revlimid
McKesson Specialty, a subsidiary of McKesson Corp., has been certified by Celgene Corp. as one of a select group of RevAssist Program contract pharmacies to launch Revlimid (lenalidomide). To reduce fetal exposure to the drug, Revlimid is available only through RevAssist, a distribution network employing only certified, contracted specialty pharmacies. Revlimid is an oral medication for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1 risk myelodysplastic syndromes (MDS) associated with a missing part of chromosome 5 (known as deletion 5q MDS).
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
